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ABSTRACT
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-
lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored 
their prognostic value in patients with advanced hepatocellular carcinoma (HCC) 
treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available 
for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning 
of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS 
(2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect 
to patients with SII < 360.
NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS 
(5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical 
covariates SII and NLR remained an independent prognostic factor for OS. The SII and 
NLR represent potential prognostic indicator in patients with advanced HCC treated 
with sorafenib.
INTRODUCTION
Hepatocellular carcinoma (HCC) represents the 
most common primary liver cancer with an increasing 
incidence [1].
The introduction of Sorafenib, currently representing 
the standard of care of advanced HCC, changed the 
clinical landscape even if a large proportion of patients 
show a limited efficacy with respect to toxic effects [2, 3, 
4, 5, 6, 7]. Until now predictive biomarkers of sorafenib 
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efficacy or resistance have yet to be identified [8, 9, 10, 
11, 12, 13].
Systemic inflammatory responses have been shown 
to reflect the promotion of angiogenesis, DNA damage and 
tumor invasion through up-regulation of cytokines [14]. 
Previous research revealed that lymphocytes play a crucial 
role in tumor defense by inducing cytotoxic cell death and 
inhibiting tumor cell proliferation and migration [15]. In 
consideration of these factors, several inflammation and 
immune-based prognostic scores, such as lymphocyte 
count, neutrophil-lymphocyte ratio (NLR), and systemic 
immune-inflammation index (SII), have been developed to 
predict survival and recurrence in cancers, including HCC 
[16, 17].
Cancer immunotherapy has made huge progress in 
the last few years. In particular, recent studies focalize 
the role of immune system in HCC. In fact, the unique 
immune response in the liver favors tolerance, which 
can represent a genuine challenge for conventional 
immunotherapy in patients with HCC [18].
Herein, we evaluated the potential role of SII, NLR 
and PLR as predictors of outcome in HCC patients treated 
with sorafenib.
RESULTS
Patient characteristics
56 patients diagnosed with HCC were consecutively 
treated with sorafenib. The patients caracteristics and 
clinical outcome show in Table 1.
SII, NLR PLR and clinical outcome
SII ≥ 360 at baseline was associated with a median 
PFS of 2.6 months (95% CI 2.0-2.9) compared to 3.9 
months (95% CI 2.8-6.2) for patients with SII < 360 (P = 
.026) (HR 2.01, 95%CI 1.07-3.75, p = 0.029) (Figure 1a). 
SII ≥ 360 was associated with a median OS of 5.6 months 
(95% CI 3.2-10.4) compared to 13.9 months (95% CI 5.7-
Table 1: Univariate analysis of progression-free survival (PFS) and overall survival (OS)
PFS No. patients (%) No. events Median PFS (95% CI) P HR (95% CI) P
Overall 56 (100) 46 2.8 (2.6-3.9) - - -
Age, years (continuous 
variable) - - - - 0.99 (0.96-1.01) 0.286
Gender
 Male 47 (83.9) 39 2.6 (2.2-2.9) 1.00
 Female 9 (16.1) 7 8.5 (5.2-18.8) 0.018 0.37 (0.16-0.87) 0.022
Etiology
 Other 25 (44.6) 19 2.9 (1.4-6.0) 1.00
 Viral 31 (55.4) 27 2.8 (2.2-5.2) 0.686 1.13 (0.62-2.07) 0.687
ECOG PS
 0 31 (55.4) 26 3.9 (2.5-8.2) 1.00
 ≥1 25 (44.6) 20 2.6 (1.8-2.9) 0.170 1.53 (0.83-2.81) 0.175
BCLC stage
 B 13 (23.2) 10 6.0 (1.4-18.8) 1.00
 C 43 (76.8) 36 2.7 (2.3-3.3) 0.060 2.01 (0.96-4.20) 0.065
Alpha-fetoprotein:
 <400 32 (59.3) 24 2.7 (2.0-3.9) 1.00
 ≥400 22 (40.7) 20 3.7 (2.3-10.8) 0.123 0.59 (0.30-1.17) 0.128
MELD score
 ≤10 44 (78.6) 37 2.8 (2.6-5.2) 1.00
 >10 12 (21.4) 9 2.6 (0.9-3.7) 0.832 1.09 (0.50-2.36) 0.833
Extrahepatic spread
 Yes 16 14 2.6 (1.8-3.9) 1.00
 No 40 32 3.3 (2.6-6.0) 0.110 0.59 (0.31-1.14) 0.116
(Continued )
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22.8) for patients with SII < 360 (P = .024) (HR 2.13, 
95%CI 1.09-4.17, p = 0.027) (Figure 1b).
SII ≥ 360 at 1 months was associated with a 
median PFS of 2.6 months (95% CI 1.8-3.3) compared to 
3.9 months (95% CI 2.8-6.2) for patients with SII < 360 
(P = .024) (HR 2.00, 95%CI 1.08-3.70, p = 0.027). SII 
≥ 360 was associated with a median OS of 5.7 months 
(95% CI 3.1-13.9) compared to 11.2 months (95% CI 
6.8-15.6) for patients with SII < 360 (P = .087) (HR 1.76, 
95%CI 0.91-3.38, p = 0.091). SII < 360 showed a higher 
percentage of response at the first sorafenib re-evaluation 
than those SII ≥ 360 (24% vs. 0%, respectively) (P = 
0.039) (Table 2).
To evaluate SII modifications during the course of 
treatment. We considered PFS and OS after stratifying 
patients into 2 groups according to SII levels at baseline 
and after second blood sample. The first group included 
patients with high (<360)-high (≥360) levels of SII, while 
the second included those with high(≥360)-low(<360), 
low(<360)-low(<360) SII. Patients in the first group had 
a median PFS of 2.5 months compared to 3.9 months for 
those in the second group (HR 1.77, 95% CI 0.93–3.36, 
p=0.08) (Figure 1c). OS was 13.9 months in the first group 
and 5.2 months in the second group (HR 2.07, 95% CI 
1.03–4.13, p=0.040) (Figure 1d).
NLR ≥ 3 was associated with a median PFS of 2.6 
months (95% CI 1.7-3.7) compared to 3.3 months (95% 
CI 2.6-6.2) for patients with NLR < 3 (P = .049) (HR 
1.84, 95%CI 0.99-3.41, p = 0.053) (Figure 1e). NLR ≥ 3 
was associated with a median OS of 5.6 months (95% CI 
2.2-10.4) compared to 13.9 months (95% CI 5.2-20.9) for 
patients with NLR< 3 (P = .058) (HR 1.87, 95%CI 0.97-
3.60, p = 0.062) (Figure 1f).
PLR ≥ 15.0 was associated with a median PFS of 
2.6 months (95% CI 2.0-5.2) compared to 2.9 months 
(95% CI 2.6-8.2) for patients with PLR < 0.15 (P = .430) 
(HR 1.30, 95%CI 0.68-2.49, p = 0.433) (Figure 1g). PLR 
< 15.0 was associated with a median OS of 6.9 months 
(95% CI 5.6-13.9) compared to 14.6 months (95% CI 2.2-
10.0) for patients with PLR≥ 15.0 (P = .815) (HR 1.09, 
95%CI 0.53-2.26, p = 0.815) (Figure 1h).
NLR and PLR modifications during the course of 
treatment show in Table 3.
The counts for neutrophils, lymphocytes and 
platelets alone without the ratio and clinical outcome show 
in Table 4.
OS No. patients (%) No. events Median OS (95% CI) P HR (95% CI) P
Overall 56 (100) 39 6.9 (5.2-14.6) - - -
Age, years 
(continuous variable) - - - - 0.98 (0.96-1.00) 0.107
Gender
 Male 47 (83.9) 32 6.7 (3.7-13.9) 1.00
 Female 9 (16.1) 7 19.0 (5.7-23.0) 0.221 0.60 (0.26-1.38) 0.226
Etiology
 Other 25 (44.6) 15 6.8 (3.7-14.6) 1.00
 Viral 31 (55.4) 24 6.9 (3.9-15.6) 0.619 1.18 (0.61-2.30) 0.620
ECOG PS
 0 31 (55.4) 24 13.9 (3.7-15.6) 1.00
 ≥1 25 (44.6) 15 6.7 (3.2-22.8) 0.794 0.91 (0.47-1.79) 0.794
BCLC stage
 B 13 (23.2) 8 15.8 (1.4-24.0) 1.00
 C 43 (76.8) 31 6.7 (3.9-13.9) 0.092 1.96 (0.88-4.36) 0.098
Alpha-fetoprotein
 <400 32 (59.3) 19 6.7 (4.5-22.8) 1.00
 ≥400 22 (40.7) 18 11.2 (3.2-15.8) 0.762 1.11 (0.57-2.13) 0.761
MELD score
 ≤10 44 (78.6) 31 11.2 (5.2-15.6) 1.00
 >10 12 (21.4) 8 6.7 (0.9-34.2) 0.696 1.17 (0.53-2.59) 0.697
Extrahepatic spread
 Yes 16 13 5.2 (3.1-14.6) 1.00
 No 40 26 10.4 (5.7-15.6) 0.257 0.68 (0.34-1.33) 0.260
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After adjusting for clinical covariates (age, gender, 
etiology, BCLC stage, ECOG performance status), SII 
and NLR remained an independent prognostic factor for 
OS (SII: HR=2.99, 95% CI 1.34-6.68, p= 0.007; NLR: 
HR= 2.36, 95% CI 1.07-5.18, p = 0.033) but not for PFS 
(HR=1.73, 95% CI 0.91-3.29, p=0.096; NLR: HR=1.81, 
95% CI 0.92-3.58, p=0.088).
DISCUSSION
In the present study, SII and NLR was show to be 
an indipendent predictor of OS for patients with HCC 
treated with sorafenib. Our results suggest that the SII 
could be a more objective marker that reflects the balance 
between host inflammatory and immune response status 
than indexes such as the PLR and NLR. In addition, our 
data have shown that a high SII basal and a month is 
associated with a worse prognosis respect other patients.
In neoplastic process, inflammatory cells are 
powerful tumor promoters; they produce an attractive 
environment for tumor growth, facilitating genomic 
instability and promoting angiogenesis [19]. Tumors are 
often infiltrated by various numbers of lymphocytes, 
macrophages and mast cells. It has been suggested that 
lymphocytes play central roles in host antitumor immune 
responses. Mouse models have shown that lymphocytes 
may control cancer outcome [20].
As an integrated indicator based on peripheral 
lymphocyte, neutrophil, and platelet counts, the predictive 
value of SII for cancer outcomes might be due to the 
function of these three types of cells. Lymphocytes and 
platelets have been proven to promote tumor development. 
In addition, recent evidence indicates that neutrophils 
enhance cancer cell invasion, proliferation, and metastasis 
and assist cancer cells with evading immune surveillance.
Several studies have shown that platelets induces 
circulating tumor cell epithelial-mesenchymal transition 
and promotes extravasation to metastatic sites [21, 22]. 
Neutrophils promote adhesion and seeding of distant 
organ sites through the secretion of circulating growth 
factors such as vascular endothelial growth factor (VEGF) 
and proteases [23, 24]. Lymphocytes play a crucial role 
in tumor defense by inducing cytotoxic cell death and 
inhibiting tumor cell proliferation and migration, thereby 
Figure 1: a. Progression-free survival (PFS) in relation to SII at baseline; b. Overall survival (OS) in relation to SII at baseline; c. 
Progression-free survival (PFS) in relation to SII modifications during the course of treatment; d. Overall survival (OS) in relation to SII 
modifications during the course of treatment; e. Progression-free survival (PFS) in relation to NLR; f. Overall survival (OS) in relation to 
NLR; g. Progression-free survival (PFS) in relation to PLR; h. Overall survival (OS) in relation to PLR.
Oncotarget67146www.impactjournals.com/oncotarget
Table 4: The counts for neutrophils, lymphocytes and platelets alone without the ratio and clinical outcome
N. pts N. events Median PFS (95% CI) p HR (95% CI) p
Neutrofili: 1.000 (1.000-1.000) 0.181
 <UNL 8 7 3.9 (2.5-11.2) 0.77 (0.34-1.75) 0.533
 < >UNL 43 35 2.8 (2.2-3.9) 1.00
 >UNL 5 4 2.3 (1.2-nr) 0.516 1.59 (0.56-4.58) 0.386
Linfociti: 1.000 (1.000-1.000) 0.317
 ≤UNL 13 13 2.6 (1.8-3.9) 1.00
 >UNL 43 33 2.9 (2.5-6.0) 0.287 0.70 (0.37-1.35) 0.291
Piastrine: 1.000 (0.996-1.003) 0.811
 ≤UNL 21 17 3.9 (2.0-8.2) 1.00
N. pts N. events Median OS (95% CI) p HR (95% CI) p
Neutrofili: 1.000 (1.000-1.000) 0.199
 <UNL 8 5 13.1 (4.5-nr) 0.57 (0.22-1.47) 0.244
 < >UNL 43 31 6.9 (3.7-14.6) 1.00
 >UNL 5 3 6.7 (2.0-nr) 0.419 1.34 (0.40-4.52) 0.639
Linfociti: 1.000 (0.999-1.000) 0.307
 ≤UNL 13 11 5.2 (2.2-19.0) 1.00
 >UNL 43 28 11.2 (5.7-15.6) 0.107 0.56 (0.27-1.15) 0.112
Piastrine: 0.999 (0.995-1.002) 0.431
 ≤UNL 21 15 6.8 (3.1-20.9) 1.00
 >UNL 35 24 6.9 (5.2-14.9) 0.655 1.16 (0.60-2.25) 0.656
Table 2: Association between SII, NLR and PLR and ORR
SII (baseline) NLR (baseline) PLR (baseline)
<360 ≥360 <3 ≥3 <15.0 ≥15.0
No. (%) No. (%) P No. (%) No. (%) P No. (%) No. (%) P
ORR
 CR+PR 5 (23.8) 0 5 (19.2) 0 5 (15.6) 0
 SD+PD 16 (76.2) 24 (100) 0.039 21 (80.8) 19 (100) 0.063 27 (84.4) 13 (100) 0.301
SII, systemic immune-inflammation index; NLR, neutrophil-to.lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ORR, 
objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
Table 3: NLR and PLR modifications during the course of treatment
N. pts PFS OSN. events HR (95% CI) p N. events HR (95% CI) p
NLR 48 41 1.08 (0.98-
1.20)
0.129 35 1.15 (1.03-1.27) 0.010
PLR 49 42 0.98 (0.94-
1.02)
0.348 36 1.01 (0.97-1.05) 0.710
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dictating the host’s immune response to malignancy 
[25]. Thus, inflammation induces changes in the cancer 
microenvironment changes that favor cancer progression.
Ipilimumab is a monoclonal antibody that works 
to activate the immune system by targeting CTLA-4, a 
protein receptor that downregulates the immune system. 
Recent works on melanoma have shown thatb derived 
neutrophil-to-lymphocyte ratio may be associated with 
response to these drugs [26, 27]. For this reason, our 
work highlights the possible benefit of a subset of patients 
with advanced hepatocellular carcinoma to treatment 
with ipilimumab. In conclusion the low cost, easy 
determination, and reproducibility of a full blood count 
make SII and NLR a promising tool for assessing HCC 
prognosis in future clinical practice.
PATIENTS AND METHODS
Patient population
This retrospective study was conducted on 56 HCC 
patients consecutively treated at our institute (Istituto 
Scientifico Romagnolo per lo Studio e la Cura dei Tumori) 
from 2012 to 2015.
We enrolled only patients receiving oral treatment 
with either 400 mg of sorafenib (consisting of 2 200-
mg tablets) twice daily. Treatment with sorafenib was 
continued until disease progression, unacceptable toxicity 
or death occurred. Disease progression was assessed using 
Modified Response Evaluation Criteria in Solid Tumors 
(mRECIST).
Statistical analysis
The aim of this analysis was to examine the 
association between baseline SII, NLR and PLR levels 
and Progression-Free Survival (PFS) and Overall Survival 
(OS) in patients with HCC treated with sorafenib.
Information on neutrophil, lymphocyte and platelet 
counts from hematologic blood tests carried out at baseline 
(the day before the start of treatment) and one month was 
collected. Complete blood counts have been carried out 
with XE-2100 (Sysmex, Kobe, Japan).
The SII was calculated as platelet count × 
neutrophil count/lymphocyte count, NLR was obtained 
by dividing the absolute neutrophil count by the absolute 
lymphocyte count, and the PLR was calculated by as 
the ratio of the absolute platelet count to the absolute 
lymphocyte count.
Association between categorical variables was 
assessed using the Fisher’s exact test, when appropriate.
PFS was defined as the time interval between the 
day of start of treatment and the day of documented 
disease progression, last follow-up visit if there was no 
progression or the day of death. OS was defined as the 
time interval between the day of start of treatment until 
the day of death or last follow-up visit. PFS and OS 
were estimated by the Kaplan-Meier method and curves 
were compared by the log-rank test. Unadjusted and 
adjusted hazard ratios (HRs) by baseline characteristics 
(age, gender, etiology, ECOG performance status) were 
calculated using the Cox proportional hazards model.
We also conducted landmark analyses to reduce 
possible confounding by time on treatment by assessing 
the impact of change in SII; NLR and PLR at 1 month 
landmark time on survival outcomes. X-tile 3.6.1 software 
(Yale University, New Haven, CT) was used to determine 
the cutoff value for baseline levels of each II. SII ≥360, 
NLR ≥3 and PLR ≥15 were considered as elevated levels.
All p values were based on two-sided testing and 
statistical analyses were performed using SAS statistical 
software version 9.4 (SAS Inc., Cary, NC, USA).
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